A clinical study of CS1002 a CTLA-4 inhibitor for Cancer.
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2018
At a glance
- Drugs CS-1002 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 08 Jan 2018 New trial record
- 29 Dec 2017 According to a CStone Pharmaceuticals media release, an investigational new drug (IND) filing has been submitted to Human Research Ethics Committees of the Ashford Cancer Center in Australia for CS1002.